The Xcelerate Keynote Series has added Moderna CMO Tal Zaks to the expert lineup of speakers set to present next Monday, Sept. 21.
As you likely know, Moderna is one of the front-runners in the COVID-19 vaccine race, and we look... Read more »
Cell therapy offers another option for addressing the most difficult blood cancer cases, but such treatments, which are engineered from a patient’s own immune cells, don’t yet work on solid tumors. Neogene Therapeutics is developing technology with the potential to bring... Read more »
Alkahest, a company that analyzes blood proteins to develop therapies that address neurological disorders including Alzheimer’s disease, is set to be acquired by partner Grifols in a $146 million deal.
Among the casualties of the COVID-19 pandemic: the credibility of government agencies entrusted with protecting public health.
The FDA this week granted emergency use authorization for convalescent plasma as a treatment for infection by the novel coronavirus. FDA Commissioner Stephen... Read more »
Fungal infections might not immediately come to mind as rare diseases, but growing resistance to older drugs means that patients who develop these infections have limited treatment options. Biotech company F2G aims to give these patients another choice. As the startup... Read more »
Patients with advanced multiple myeloma have a new treatment option with the FDA’s approval of a GlaxoSmithKline drug that targets B-cell maturation antigen, a protein found on the surface of cancerous plasma cells.
The agency OK’d the London-based pharma giant’s cancer... Read more »
A MorphoSys antibody drug developed for diffuse large B-cell lymphoma (DLBCL) has won FDA approval, providing an alternative to cumbersome and risky CAR-T therapies to treat the cancer.
The late Friday approval for the drug, tafasitamab (Monjuvi), covers adults whose... Read more »
Scientists know that proteins called solute carrier (SLC) transporters move substances important to metabolism across cellular membranes. But can drugs effectively hit these proteins to treat disease? Roche is paying startup Jnana Therapeutics $40 million to find out.
GlaxoSmithKline is expanding its capabilities in messenger RNA (mRNA) research through a new alliance with CureVac spanning up to five programs targeting infectious disease pathogens.